|
WO2021007101A1
|
|
Method and molecules
|
|
WO2020240502A2
|
|
Combination therapy
|
|
WO2020210650A1
|
|
Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
|
|
US2020317803A1
|
|
Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors
|
|
WO2020185986A1
|
|
Decreasing staphylococcus aureus infections in colonized patients
|
|
WO2020128908A2
|
|
Methods for selection and expansion of t cells expressing pd-1
|
|
US2020190598A1
|
|
Blood-based tumor mutation burden predicts overall survival in nsclc
|
|
WO2021080608A1
|
|
Branched moiety for use in conjugates
|
|
US2020126636A1
|
|
Methods for determining treatment for cancer patients
|
|
WO2020081783A2
|
|
Anti-ox40, anti-pd-l1 and anti-ctla-4 antibodies for treating tumors
|
|
TW202035443A
|
|
Combinations of anti-staphylococcus aureus antibodies
|
|
TW202028232A
|
|
Antibodies directed against staphylococcus aureus leukotoxins
|
|
WO2020051331A1
|
|
Methods of cell selection
|
|
WO2020023644A2
|
|
Antibody directed against s. aureus clumping factor a (clfa)
|
|
WO2019164870A1
|
|
Expression of signature mrnas for identifying patients responsive to anti-pd-l1 antibody therapy
|
|
BR112020008978A2
|
|
bispecific fusion polypeptides and their methods of use
|
|
AU2018318435A1
|
|
Compositions and methods for treatment of atopic dermatitis and treatment selection
|
|
CN110913928A
|
|
Device attachment for digitally monitoring usage of an automatic injector to improve compliance, remote patient monitoring, and adherence
|
|
WO2019025983A1
|
|
Bcma monoclonal antibody-drug conjugate
|
|
WO2018195270A1
|
|
E-connected auto-injectors
|
